$RDHL Deal Alert RedHill Biopharma is selling its Talicia H. pylori drug business to Apotex Health Corp in an $18 million upfront deal - with up to $35 million more in potential milestone payments on the table. Talicia treats H. pylori, a bacterial infection linked to stomach cancer and ulcers that affects roughly 35% of the U.S. population. RedHill held a 70% stake in the drug; Apotex already owned the remaining 30% through its earlier acquisition of Cumberland Pharmaceutical's branded business. For RedHill, this isn't just a sale - it's a strategic pivot. The company says the deal strengthens its balance sheet and funds the next phase of expanding its gastrointestinal commercial portfolio, as it works toward profitability. Read more: https://www.tipranks.com/news/redhill-sells-its-talicia-h-pylori-drug-business-to-apotex-in-18m-deal-to-fuel-growth Not financial advice. Always do your own research. #RedHill #RDHL #Biotech #Pharma #StockNews #TipRanks #MergersAndAcquisitions